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Abstract The association between cardiac failure and
renal function impairment has gained wide recognition
over the last decade. Both structural damage in the form of
systemic atherosclerosis and (patho) physiological hemo-
dynamic changes may explain this association. As regards
hemodynamic factors, renal impairment in chronic heart
failure is traditionally assumed to be mainly due to a
decrease in cardiac output and a subsequent decrease in
renal perfusion. This will lead to a decrease in glomerular
ﬁltration rate and a compensatory increase in tubular
sodium retention. The latter is a physiological renal
response aimed at retaining ﬂuids in order to increase
cardiac ﬁlling pressure and thus renal perfusion. In heart
failure, however, larger increases in cardiac ﬁlling pressure
are needed to restore renal perfusion and thus more volume
retention. In this concept, in chronic heart failure, an
equilibrium exists where a certain degree of congestion is
the price to be paid to maintain adequate renal perfusion
and function. Recently, this hypothesis was challenged by
new studies, wherein it was found that the association
between right-sided cardiac ﬁlling pressures and renal
function is bimodal, with worse renal function at the
highest ﬁlling pressures, reﬂecting a severely congested
state. Renal hemodynamic studies suggest that congestion
negatively affects renal function in particular in patients in
whom renal perfusion is also compromised. Thus, an
interplay between cardiac forward failure and backward
failure is involved in the renal function impairment in the
congestive state, presumably along with other factors. Only
few data are available on the impact of intervention in
volume status on the cardio-renal interaction. Sparse data
in cardiac patients as well as evidence from cohorts with
primary renal disease suggest that speciﬁc targeting of
volume overload may be beneﬁcial for long-term outcome,
in spite of a certain further decrease in renal function, at
least in the context of current treatment where possible
reﬂex neurohumoral activation is ameliorated by the
background treatment by blockers of the renin–angioten-
sin–aldosterone system.
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Introduction
The association between cardiac failure and renal function
impairment has gained wide recognition over the last
decade. The interest in the association is fuelled by the
independent predictive role of renal function impairment
for prognosis, with a worse prognosis in subjects with
worse renal function [1]. This has raised ample interest in
the nature of the renal function impairment in chronic heart
failure and fuelled the hypothesis that speciﬁc renal pro-
tection may be of beneﬁt in chronic heart failure.
Both renal hemodynamic factors and structural renal
abnormalities contribute to renal function impairment in
chronic heart failure. In subjects where chronic heart fail-
ure is due to ischemic cardiac abnormalities, generalized
vascular damage including renal arteriolosclerosis is
relatively common. In this concept, renal and cardiac
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effects of the process of atherosclerosis on the heart and on
the kidney. In non-ischemic heart failure, such as due to
myocarditis, the kidneys can be considered as intrinsically
normal, at least initially, and the renal function impairment
appears to be more directly reﬂective of the cardiac
hemodynamic impairment [2].
Hemodynamic factors are traditionally considered a
main driving force in the renal function impairment in
heart failure. A reduction in cardiac output leads to
impairment of renal perfusion. The latter leads to renal
sodium retention, as a compensatory response to restore
renal perfusion pressure. In principle, this is an adequate
homeostatic response that increases cardiac ﬁlling pressure
and hence cardiac output according to the Frank–Starling
curve of the heart, with consequently restoration of renal
perfusion and renal function toward normal values. In heart
failure, however, the association between cardiac ﬁlling
pressure and cardiac output is disturbed, so the restoration
of cardiac output is obtained at the expense of an abnormal
rise in cardiac ﬁlling pressure, contributing to the conges-
tive state. In this classical concept, the congestive state is
the price to be paid for restoration of renal perfusion
and hence renal function. Recent ﬁndings shed new light
on the association between chronic heart failure, the
derangements in hemodynamics and volume status, and
renal function impairment and warrant a different appraisal
of the role of renal perfusion impairment, the congestive
state, and renal impairment in chronic heart failure, as will
be reviewed below.
Role of the kidney in the homeostasis of circulating
volume
An adequate response of the kidney to changes in perfusion
pressure and volume status is a central factor in the normal
homeostasis of circulating volume that involves a coordi-
nated response of the vascular and tubular part of the
nephron. Under normal circumstances, the auto-regulatory
capacity of the glomerular microcirculation allows ﬁltra-
tion capacity to remain constant over a wide range of
pressures, thus ensuring stable and continuous excretion of
metabolic waste products despite changes in volume status
and blood pressure. Meanwhile, the tubular component of
the homeostatic response ensures stability of sodium and
volume balance by adapting proximal and distal tubular
sodium reabsorption. These adaptive glomerular and
tubular changes occur in response to altered renal perfusion
pressure, as well as in response to changes in volume status
without changes in renal perfusion pressure. Thus, renal
adaptive capacity allows the body to maintain circulatory
homeostasis over a widely different range of sodium and
ﬂuid intake and provides our evolutionary defense against
volume depletion by blood loss and dehydration.
Renal response to perfusion impairment
During impairment of renal perfusion pressure, glomerular
ﬁltration rate (GFR) is maintained by a two-step hemody-
namic adaption. First, pre-glomerular (afferent) vasodilata-
tion occurs by the afferent myogenic response, reﬂecting the
classicalauto-regulationresponseofthekidneythatservesto
maintain both glomerular ﬂow and pressure, and hence ﬁl-
tration, with an additional regulation of afferent tone by the
tubuloglomerular feedback loop. Brieﬂy, the latter mecha-
nism works as follows: renal perfusion decline leads to
compensatorytubularsodiumreabsorptionandthereforetoa
reduction in distal tubular sodium delivery, which is sensed
bythemaculadensa.Lowerdistalsodiumdeliverydecreases
adenosine concentration and therefore adenosine-a1 recep-
tor activity, causing afferent vasoconstriction, commonly
known as tubuloglomerular feedback. When faced with a
further fall in perfusion pressure, post-glomerular (efferent)
vasoconstriction occurs as the next resort of the auto-
regulatory response. This ensures preservation of ﬁltration
pressure in glomerular capillaries at the expense of a further
fall in perfusion. Thus, the proportion of renal perfusion
effectivelyﬁltered,theﬁltrationfraction(FF)isincreased,as
a distinguishing feature of increased efferent vascular tone.
Increased activity of the renin–angiotensin–aldosterone
system (RAAS), elicited by the decreased renal perfusion
pressure, plays an important role in the renal hemodynamic
and tubular response to perfusion impairment. First, the
efferent vasoconstriction is mainly mediated by angiotensin
II. Concomitant intra-renal production of vasodilator pros-
taglandins precludes inadvertent vasoconstrictor effects of
angiotensin II on the afferent arteriole that could threaten
ﬁltration pressure under these circumstances. Second, the
concomitant increase in tubular sodium reabsorption is
mediated by angiotensin II, by direct tubular effects as well
as by an increase in aldosterone. The ensuing renal sodium
retention is facilitated by the concomitant decrease in
natriuretic peptides. Angiotensin II furthermore contributes
to maintenance of blood pressure by its vasoconstrictor
effects on the systemic vascular bed.
The role of renal perfusion impairment in chronic
heart failure
In chronic heart failure, whether with reduced or preserved
ejection fraction, considerable impairment of renal perfu-
sion occurs due to the decrease in cardiac output. Even if
cardiac index is only mildly impaired, the perfusion
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123impairment can be considerable [3, 4]. The reduction in
renal perfusion is the main determinant of the impairment
in renal function that is usually observed in heart failure
[5]. It would be logical to assume that the reduction in renal
perfusion and renal function is proportional to the decrease
in cardiac output. However, the association between car-
diac index and renal function has been notoriously difﬁcult
to demonstrate. In several studies, improvement in cardiac
index or improvement in pulmonary wedge pressure did
not adequately predict improvement in renal function in
heart failure patients [6–9]. To understand this seeming
discrepancy, it is important to realize that the association
between cardiac output and impairment of GFR is not
mono-dimensional.
First, renal perfusion and hence GFR can be affected by
pre-existing renal arteriolosclerosis. Second, the renal auto-
regulatory capacity can maintain GFR in spite of renal
perfusion impairment, by tubuloglomerular feedback and
afferent vasodilatation, and by increased RAAS activity
and consequent efferent vasoconstriction. This adaptive
mechanism is readily apparent when renal perfusion is
measured concomitantly with GFR, from the increase in FF
that is usually present in patients with chronic heart failure.
Accordingly, when only data on (estimated) GFR are
available, the association between cardiac index and renal
changes is obscured. It is only in advanced heart failure,
when renal perfusion is severely impaired, that FF
decreases sharply, probably because renal perfusion is
maintained at the expense of locomotor muscle perfusion
initially [10] and not until heart failure advances, will renal
perfusion decrease below the lower threshold of auto-
regulatory capacity [5]. Renal auto-regulation itself may
become impaired due to decreased availability of nitric
oxide [11], which impairs tubuloglomerular feedback.
Decreased nitric oxide availability, caused by endothelial
dysfunction, is not only seen in heart failure but also in
diabetes mellitus, inﬂammation, and atherosclerosis. In
such a situation, GFR becomes strongly dependent on
blood pressure that is, understandably, very low as well
with consequently a sharp further decrease in GFR [5]. It
should be noted that currently most patients with chronic
heart failure are treated by RAAS blockade for its cardio-
protective effects. RAAS blockade, however, impairs the
efferent contribution to auto-regulatory capacity and thus
can aggravate the GFR impairment. The latter can, to a
certain extent, be considered to be a price to be paid for the
cardio-protective effects of the RAAS blockade.
The above described sequence of events represents the
pre-renal component of the GFR impairment in chronic
heart failure and corresponds to the renal changes that
occur in other pre-renal conditions, such as severe dehy-
dration and volume depletion. Accordingly, when renal
perfusion is restored by volume repletion, renal function
will improve. The major difference between pre-renal
failure due to pure volume deﬁcit and renal function
impairment in chronic heart failure is, obviously, the con-
gestive state. In patients with pure volume deﬁcit, volume
repletion is the single effective treatment, whereas in
chronic heart failure, volume repletion measures can be
expected to worsen the congestive state.
In the clinical management of heart failure, therefore,
the usual concept on volume management is that of a trade-
off: measures to improve congestion, diuretics and dietary
sodium restriction will do so at the expense of a further
decrease in renal function. Vice versa, when severe renal
function impairment prompts for accepting a positive vol-
ume balance by reducing diuretics or a more liberal sodium
intake, the improvement in renal function occurs at the
expense of worsening congestion.
Association between the congestive state and renal
function
Until recently, it was assumed that the congestive state as
such did not impact on renal function, despite a few very
old studies [12–14] that suggested an adverse effect of high
venous pressure on renal function. Several studies, how-
ever, recently demonstrated an association between venous
congestion and worse renal function, in various populations
with cardiac impairment from different origin with both
reduced and preserved ejection fraction.
A large retrospective analysis in 2557 patient from our
center that underwent right heart catheterization showed
that central venous pressure (CVP) is associated with
estimated GFR (eGFR) in a bimodal fashion, with the
highest eGFR at a CVP of approximately 3 mmHg and a
progressively lower eGFR in subjects with CVP above
5–6 mm Hg, comprising approximately one-third of the
population. Remarkably, is shown in Fig. 1, this bimodal
association was independent of cardiac index, demon-
strating that the adverse impact of high CVP on eGFR was
not merely due to the patients with high CVP being a
subset in a very poor condition including worse cardiac
output. In fact, the decrease in eGFR at higher CVP was, if
anything, steeper in subjects with a relatively preserved
eGFR. Elevated CVP was also an independent predictor for
mortality [15]. Not only directly measured CVP was found
to be related to renal function. In a separate study in 2647
patients with systolic heart failure, presence of congestive
symptoms, such as peripheral edema, elevated jugular
venous pressure, orthopnea, and ascites were associated
with worse eGFR and, moreover, with mortality [16].
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impairment
The separate contributions of renal perfusion impairment
and congestion were analyzed in a population of patients
with predominantly right-sided heart failure due to primary
or secondary pulmonary hypertension, screened for lung
transplantation at our center. Their work-up included renal
hemodynamic measurements as well as right-sided heart
catheterization. In this population with a mean true GFR of
73 ml/min/1.73m2, renal blood ﬂow and right atrial pres-
sure were the only determinants of GFR on multivariate
analysis, with a worse GFR in subjects with lower renal
blood ﬂow and higher right atrial pressure. Remarkably,
elevated right atrial pressure did not affect GFR in subjects
with preserved renal blood ﬂow, whereas it was associated
with a signiﬁcant further reduction in GFR in subjects in
whom renal blood ﬂow was impaired (Fig. 2)[ 17]. This
leads to the concept that venous congestion or backward
failure impairs GFR only, or preferentially, when forward
failure is concomitantly present.
The mechanisms of the adverse effect of high venous
pressure on renal function are incompletely elucidated.
Animal studies, in a canine model, where induction of
volume overload was associated with a rise in renal inter-
stitial pressure along with a decline in renal perfusion and
renal function, suggest that elevated venous pressure may
translate into inappropriate elevation of renal interstitial
pressure as a possible mechanism [18].
In addition, it has been shown that venous congestion
and associated endothelial stretch increase the production
of pro-inﬂammatory cytokines [19], such as tissue necrosis
factor-a, which are associated with sodium retention,
renal hypertrophy, and nephropathy [20, 21]. Additional
production of reactive oxygen species may reduce nitric
oxide availability, leading to peripheral and systemic
vasoconstriction [22]. This does not only increase cardiac
ﬁlling pressure via increased central blood volume but also
reduces renal perfusion.
Implications for treatment: a re-appraisal of volume
targeting in chronic heart failure
The evidence that congestion as such is associated with an
adverse effect on renal function challenges the trade-off
concept that volume repletion, with acceptance of a certain
worsening of congestion, will invariably improve renal
function. In fact, the curve in Fig. 1 suggests that careful
targeting of the congestive state can lead to improvement
in renal function in subjects with severely elevated CVP,
which would be in line with the aforementioned animal
study. It should be noted here that the associations between
CVP and eGFR in human populations were cross-sectional
and did not include interventions in volume status. In fact,
recent data on intervention in volume status in heart failure
are scarce.
Targeting volume status can be effectuated by dietary
sodium restriction, diuretics, and the combination, whereas
in severe heart failure, hyponatremia can prompt for ﬂuid
restriction as well. Ultraﬁltration can be used as a last
resort in patients with severe congestion along with poor
cardiac output.
The ESC guidelines on acute and chronic heart failure
[23] identify the effect of dietary sodium restriction as one
of the gaps in the current evidence. Studies on natriuretic
efﬁcacy of diuretics, however, have shown that negative
Fig. 1 Distribution of central venous pressure and curvilinear
relationship between central venous pressure and estimated glomerular
ﬁltration rate in 2557 patients that underwent right heart catheteriza-
tion at the uMCG between 1989 and 2006. Curve is adjusted for age,
gender, and cardiac index. (from: Damman et al. ref 15)
Fig. 2 Relative contributions of right atrial pressure (RAP) and renal
blood ﬂow (RBF) on glomerular ﬁltration rate (GFR, Y-axis, ml/min/
1.73 m
2) Error bars represent 95% CI. * P\0.001 for difference
with high RAP, low RBF. ? : P\0.01 for difference with low RAP,
low RBF. (from: Damman et al. ref 17)
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123volume balance is difﬁcult to achieve by diuretics when
sodium intake remains high, especially when the kidney is
avidly retaining sodium [24]. It seems logical therefore to
aim for dietary sodium restriction in patients where diuretic
treatment is considered to be indicated. This requires that
patients should be educated concerning the salt content
of food, as recommended by the guidelines. The latter
is important as, ﬁrst, salt content of the western diet
(9–12 g/day) contains approximately double the amount
recommended for the general population, i.e., 5–6 g/day,
and moreover, 75–80% of dietary sodium intake derives
from pre-manufactured food products. In the clinical
management of heart failure, the actual adherence to die-
tary sodium restriction is rarely veriﬁed, but it is likely that
many patients ingest excess sodium without being aware of
it, as has been shown in studies in chronic kidney disease,
where dietary sodium intake, as apparent from 24-hour
sodium excretion, is approximately similar to the general
population, despite efforts to reduce salt intake [25–27].
Use of diuretics is, in different guidelines [23, 28],
limited to patients with symptoms of congestion. This
conservative use of diuretics is mainly based on two con-
cerns. First, during therapy with diuretics, GFR tends to
decline [29], and reduction of GFR in general is a poor
prognostic sign. Second, diuretics induce excess neuro-
hormonal activation, in particular of plasma renin activity
and aldosterone [30], which could adversely affect out-
come. However, in the current era, with most patients
being treated with RAAS blockade, often in combination
with beta-blockade, the signiﬁcance of the latter may have
diminished [23, 28], although concern remains on the
direct pro-ﬁbrotic effects of aldosterone on the heart and
the kidney [31]. Aldosterone antagonists therefore look
promising as reno-protective agents [32], but newer
B-blockers may also yield protective effects on renal
function [33]. These drugs act via an effect on intrarenal
vascular resistance and may therefore affect renal blood
ﬂow and thus GFR. Larger trials in heart failure are needed
to study their effect on renal function in heart failure.
Recentdata,however,warrantare-appraisaloftheimpact
of volume targeting on GFR in patients with heart failure. It
should benotedﬁrstthatadiuretic-induceddecreaseinGFR
in patients on RAAS blockade reﬂects reversible renal
hemodynamic changes rather than persistent renal damage.
This is probably due to the impaired autoregulation under
these conditions. Withdrawal of diuretics or restoration of
volumestatusbyaliberalsodiumintakewillrestoreGFR,as
demonstrated in renal patients (Fig. 3). Interestingly, in
these renal patients, the treatment-induced decrease in GFR
predicts a favorable long-term renal outcome [34], probably
because it reﬂects the efﬁcacy of RAAS blockade apparent
from the consequent decrease in ﬁltration pressure. A
corresponding ﬁnding was recently reported from a
well-performed study in decompensated heart failure
patients [35], where subjects aggressively treated with
diuretics had worse renal function, but 180-day mortality
was reduced in these subjects, when compared to subjects
treated more conservatively. Worsening of renal function
may therefore be accepted upon start of therapy with
diuretics or sodium restriction (Fig. 3).
Even more recently, results from the DOSE trial were
released, wherein subjects admitted to the hospital with
acute decompensated heart failure were treated with either
diuretics continuously or via bolus and either normal or
high doses. Subjects with higher doses of diuretics fared
better subjectively, which was associated with more weight
loss and greater urinary output. The greater rise of serum
creatinine in this group was completely reversible after
3 weeks [36].
Therefore, data on (estimated) renal function in a
decompensated state should be interpreted with caution as
worsening GFR may reﬂect both poor prognosis and proper
treatment response, which is associated with good prog-
nosis. Without information on ﬁltration fraction or renal
perfusion, which is usually not readily available, eGFR and
serum creatinine are therefore poor prognostic markers of
renal function during acute decompensated heart failure.
Due to these reasons, it has been suggested that blood urea
nitrogen/creatinine ratio may be a better prognostic marker
in ADHF than serum creatinine or estimated GFR [37].
Fig. 3 Graph illustrating the reversibility of diuretic-induced
decrease in renal function (creatinine clearance, left Y-axis) and the
long-term rate of renal function in renal patients on RAAS blockade
(RAASi): dotted lines. At time point -4, diuretic treatment is
withdrawn, with continuation of the RAASi. This results in a rise in
renal function, demonstrating the volume dependency of renal
function during RAASi, and its reversibility. At re-institution,
necessitated by the concomitant rise in proteinuria (lower dotted
line), creatinine clearance decreases again, with a concurrent decrease
in proteinuria. The drawn lines A and B represent estimation of rate of
long-term renal function loss, without and with taking into consid-
eration the reversible impact of the change in volume status by the
diuretic. (from: Slagman et al. ref 34)
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provide clues that suggest proper attention for volume
targeting will be beneﬁcial in heart failure. This not only
applies to amelioration of the congestive state and hyper-
tension but notably also to the potentiation of the effect of
RAAS blockade in those conditions [38, 39], with con-
comitant beneﬁcial effects on hard end points [40]. Con-
sidering the main role of RAAS blockade in the clinical
management of heart failure, it might be worthwhile to
consider a systematic re-appraisal of the role of dietary
sodium restriction and diuretics in the management of heart
failure, especially in view of the fact that counseling on
sodium restriction for a short period may bear signiﬁcant
long-term effects in terms of reductions in cardiovascular
mortality [40]. The strategy for volume targeting in heart
failure will usually require both dietary sodium restriction
and diuretics to be sufﬁciently effective. As noted above,
diuretics are insufﬁciently effective in the presence of high
sodium intake [24]. Whereas the effects of low sodium diet
and diuretics exert more or less similar effects on volume
status, it should be noted that they may differ in other
effects relevant to heart failure patients, such as for
instance serum potassium. Of note, in renal patients, recent
data showed that diuretic treatment affects EPO production
when used in conjunction with RAAS blockade [41]i n
spite of a well-preserved renal function, whereas low
sodium diet does not (Fig. 4). Considering the prognostic
impact of EPO levels in heart failure, and the corre-
sponding treatment regimen, this might bear relevance to
heart failure patients as well. Corresponding data for heart
failure patients are not available yet, but the data in renal
patients suggest that it would be worthwhile to explore not
only the effects of volume targeting but also to address
whether it matters for long-term outcome by which strategy
the volume correction is achieved.
Conclusions
The traditional concept of renal function decline as being
merely due to impaired perfusion in heart failure has
recently been challenged from several angles. Increasing
evidence seems to suggest a strong role for venous con-
gestion in the pathogenesis of renal function impairment in
heart failure, in particular when perfusion is impaired as
well. Observational and interventional data in cardiac and
renal patients suggest that therapy aimed at reducing vol-
ume overload may yield beneﬁcial effects on hard end
points, despite a reduction in renal function at onset of
therapy. Dietary sodium intake is a logical target for
Fig. 4 Proteinuria and
hematological parameters in
renal patients during different
treatment regimens, during low
(open bars) and high (gray bars)
sodium diet. Low sodium diet
does not affect hemoglobin or
EPO level, neither during
placebo nor during losartan.
Losartan leads to a decrease in
hemoglobin level, and
hydrochlorothiazide 25 mg/day
added to losartan leads to a
further decrease in hemoglobin,
along with a decrease in EPO
level, and the observed/
predicted ratio for EPO.
(from: Slagman et al. ref 41)
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123intervention, which requires, however, a better awareness
of sodium intake and deliberate efforts to change dietary
habits. Results in the general population suggest that
counseling on dietary sodium intake improves cardiovas-
cular risk long after cessation of counseling. Reducing
sodium intake may prove to be an effective yet cheap
intervention. More studies to conﬁrm and optimize the
beneﬁcial effects of volume targeting in congestive heart
failure are warranted.
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